Antipsychotic Drugs: Technologies and Global Markets
LONDON, Sept. 24, 2018 /PRNewswire/ --
Report Scope:
This report provides a detailed description of the market for antipsychotic drugs.The report highlights the current and future market potential of antipsychotic drugs and provides a detailed analysis of the competitive environment, regulatory scenario, technological advancements, patent analysis, pipeline analysis, drivers, restraints, opportunities and trends in the market.
Download the full report: https://www.reportbuyer.com/product/5569333
The report also covers market projections through 2023, as well as market shares for key market players. The report segments the market for antipsychotic drugs based on mechanism of action, disease indication and geography.
Based on mechanism of action, the market is segmented into D2 antagonists, D2/5HT2A antagonists and D2 partial agonists.The market size includes both branded and generic drugs.
Based on disease indication, the market is segmented into schizophrenia, bipolar disorder, major depressive disorder (MDD), and other diseases including anxiety, autism and dementia. By geography, the market has been segmented into the North America, Europe, Asia-Pacific, South America, and Middle East and Africa regions. The North America region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., France, Italy, Spain and the rest of Europe. Asia-Pacific includes China, India, Japan and the rest of Asia-Pacific. For market estimates, data has been provided for 2017 as the base year, with forecasts for 2018 through 2023.
Report Includes:
- 22 data tables and 36 additional tables
- An overview of the global market for antipsychotic drugs
- Analyses of global market trends, with data from 2017, estimates for 2018 and projections of CAGRs through 2023
- Country specific data and analysis for United States, Canada, Mexico, UK, France, Germany, Italy, Spain, China, India and Japan
- Definition, history and types of antipsychotic drugs
- An understanding on receptor target of antipsychotic drugs, including dopamine, serotonin, glutamate, tachykinin and glucocorticoid
- Coverage of various psychotic diseases and their indication including schizophrenia, bipolar disorder, major depressive disorder (MDD), anxiety, autism and dementia
- Comprehensive company profiles of key players in the market, including Alexza Pharmaceuticals, Dr. Reddy's Laboratories, Ltd., Eli Lilly and Co., Johnson & Johnson, Teva Pharmaceutical Industries, Ltd., and Zydus Pharmaceuticals (USA), Inc.
Summary
The global market for antipsychotic drugs was estimated at approximately REDACTED in 2017.The market is forecast to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED by 2023.
The global market is segmented based on the drug's mechanism of action, disease indication and region.
Among the mechanism of action segments, D2 partial agonists are expected to grow at the industry's highest rate, owing to innovative drug formulations, the protection of multiple patents on the drugs and the strong product pipelines of key players. The market for D2 antagonists is anticipated to show declining growth rates due to the severe side effects associated with the drugs and the high rate of discontinuation and withdrawal of these drugs from the market.
Scope of Report
This report provides a detailed description of the market for antipsychotic drugs.The report highlights the current and future market potential of antipsychotic drugs and provides a detailed analysis of the competitive environment, regulatory scenario, technological advancements, patent analysis, pipeline analysis, drivers, restraints, opportunities and trends in the market.
The report also covers market projections through 2023, as well as market shares for key market players.The report segments the market for antipsychotic drugs based on mechanism of action, disease indication and geography.
Based on mechanism of action, the market is segmented into D2 antagonists, D2/5HT2A antagonists and D2 partial agonists.The market size includes both branded and generic drugs.
Based on disease indication, the market is segmented into schizophrenia, bipolar disorder, major depressive disorder (MDD), and other diseases including anxiety, autism and dementia. By geography, the market has been segmented into the North America, Europe, Asia-Pacific, South America, and Middle East and Africa regions. The North America region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., France, Italy, Spain and the rest of Europe. Asia-Pacific includes China, India, Japan and the rest of Asia-Pacific. For market estimates, data has been provided for 2017 as the base year, with forecasts for 2018 through 2023.
Reasons for Doing This Study
Antipsychotic drugs were one of the largest classes of pharmaceutical drugs sold in the U.S. in 2010. A period of dynamic change in the market for antipsychotic drugs occurred during the period 2011 to 2016, when patents expired for major blockbuster drugs and the market began to experience the emergence of low-cost generic drugs. At the same time, several unique and innovative formulations of antipsychotic drugs were launched onto the market. New approaches for the treatment of psychosisrelated indications were pursued by pharmaceutical companies, as many of them looked beyond firstand second-generation antipsychotic drugs. These new antipsychotic drugs, with novel mechanisms of action or improved delivery systems, will provide powerful new alternatives for currently prescribed antipsychotic drugs.
Download the full report: https://www.reportbuyer.com/product/5569333
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com
SOURCE ReportBuyer
Share this article